TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma

Phase 1 Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00243763

Enrollment

Registered

2005-10-25

Start date

Unknown

Completion date

Unknown

Last updated

2009-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

Refractory Multiple Myeloma or, Relapsed Multiple Myeloma

Brief summary

The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).

Interventions

DRUGTKI258

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Confirmed diagnosis of multiple myeloma * Evidence of relapsed or refractory disease

Exclusion criteria

* Intracranial disease or epidural disease * Clinically significant cardiac disease * Diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Maximum tolerated dose	—
Dose limiting toxicity	—
Safety profile	—

Secondary

Measure	Time frame
Evaluation of pharmacokinetics and pharmacodynamics	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026